Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment.
New York, United States
238 employees
Post Ipo Equity
Total: $777.00M
Biotechnology, Health Care +1
General Information
Get notified when Nuvation Bio moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Nuvation Bio
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Nuvation Bio
Taxonomy: biopharmaceutical company, oncology, cancer treatment, therapeutic candidates, proprietary portfolio, novel, mechanistically distinct, difficult-to-treat cancers, David Hung, Medivation Inc., prostate cancer medicine, biopharma industry, New York, San Francisco
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | 10 |
|
11 Feb 2021 |
| Series A | •••••• | - | 28 Oct 2019 |
Nuvation Bio Alternatives & Competitors
Precision Oncology, Redefined.
We’re focused on creating a world where no life is cut short by cancer or other serious diseases.
Regaining Cell Cycle Control
vs
Sunesis Pharmaceuticals, Inc.
FAQ About Nuvation Bio
Don't just browse. Track.
Signal Tracker monitors Nuvation Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
